Advertisement

Molecular Neurobiology

, Volume 55, Issue 5, pp 3676–3683 | Cite as

A Trans-acting Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal

  • Miguel Alves-Ferreira
  • Teresa Coelho
  • Diana Santos
  • Jorge Sequeiros
  • Isabel Alonso
  • Alda Sousa
  • Carolina Lemos
Article

Abstract

Although all familial amyloid polyneuropathy (FAP) ATTRV30M patients carry the same causative mutation, early (<40) and late-onset forms (≥50 years) of FAP may coexist in the same family. However, this variability in age at onset is still unexplained. To identify modifiers closely linked to the TTR locus that may in part be associated with age at onset of FAP ATTRV30M, in particular in a group of very early-onset patients (≤30 years) when compared with late-onset individuals. A clinical genetic study at a referral center comprising a sample of 910 Portuguese individuals includes 589 Val30Met carriers, 102 spouses, and 189 controls from the general population. Haplotype analysis was performed, using eight intragenic single nucleotide polymorphisms (SNPs) at the TTR locus. We compared haplotypes frequency in FAP samples and controls and in parent-offspring pairs using appropriated statistical analysis. Haplotype A was the most common in the general population. Noteworthy, haplotype C was more frequent in early-onset (<40) than in late-onset patients (≥50 years) (p = 0.012). When comparing allelic frequencies of each SNP within haplotype C between “very early” (≤30 years) and late-onset (≥50 years) cases, the A allele of rs72922947 was associated with an earlier onset (p = 0.009); this remained significant after a permutation-based correction. Also, the heterozygous genotype (GA) for this SNP was associated with a decrease in mean age at onset of 8.6 years (p = 0.014). We found a more common haplotype (A) linked to the Val30Met variant and a possible modulatory trans effect on age at onset. These findings may lead to potential therapeutical targets.

Keywords

Familial amyloid polyneuropathy (FAP) Transthyretin-related amyloidosis Trans effect Transthyretin (TTR) Age at onset Haplotype 

Notes

Acknowledgements

The authors thank all the patients and families for participating in this study and Vanessa Costa (from Unidade Corino de Andrade (UCA), Centro Hospitalar do Porto (CHP)) for all the help in data collection. This work was supported by grants of Fundação para a Ciência e Tecnologia, FCT [PTDC/SAU-GMG/100240/2008 and PEsT], cofunded by ERDF and COMPETE; and by Financiamento Plurianual de Unidades de Investigação (FCT).

Compliance with Ethical Standards

Conflict of Interest

M.A.F. and D. S. have received research support from a FCT fellowship (SFRH/BD/101352/2014 and SFRH/BD/91160/2012, respectively). T. C.’s institution has received support from FoldRx Pharmaceuticals, which was acquired by Pfizer Inc. in October 2010; T. C. has served on the scientific advisory board of Pfizer Inc. and received funding from Pfizer Inc. for scientific meeting expenses (travel, accommodations, and registration). She currently serves on the THAOS (natural history disease registry) scientific advisory board. J. S., I. A., A. S., and C. L. report no disclosures.

References

  1. 1.
    Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75(3):408–427CrossRefPubMedGoogle Scholar
  2. 2.
    Benson MD (2012) Pathogenesis of transthyretin amyloidosis. Amyloid 19(Suppl 1):14–15. doi: 10.3109/13506129.2012.668501 CrossRefPubMedGoogle Scholar
  3. 3.
    Sousa A, Coelho T, Barros J, Sequeiros J (1995) Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 60(6):512–521. doi: 10.1002/ajmg.1320600606 CrossRefPubMedGoogle Scholar
  4. 4.
    Sequeiros J, Saraiva MJ (1987) Onset in the seventh decade and lack of symptoms in heterozygotes for the TTRMet30 mutation in hereditary amyloid neuropathy-type I (Portuguese, Andrade). Am J Med Genet 27(2):345–357. doi: 10.1002/ajmg.1320270213 CrossRefPubMedGoogle Scholar
  5. 5.
    Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O (1993) Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 43(5):288–294CrossRefPubMedGoogle Scholar
  6. 6.
    Saporta MA, Zaros C, Cruz MW, Andre C, Misrahi M, Bonaiti-Pellie C, Plante-Bordeneuve V (2009) Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families. Eur J Neurol 16(3):337–341. doi: 10.1111/j.1468-1331.2008.02429.x CrossRefPubMedGoogle Scholar
  7. 7.
    Munar-Ques M, Saraiva MJ, Viader-Farre C, Zabay-Becerril JM, Mulet-Ferrer J (2005) Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid 12(1):54–61CrossRefPubMedGoogle Scholar
  8. 8.
    Ikeda S, Hanyu N, Hongo M, Yoshioka J, Oguchi H, Yanagisawa N, Kobayashi T, Tsukagoshi H et al (1987) Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain 110(Pt 2):315–337CrossRefPubMedGoogle Scholar
  9. 9.
    Lemos C, Coelho T, Alves-Ferreira M, Martins-da-Silva A, Sequeiros J, Mendonca D, Sousa A (2014) Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry 85(3):326–330. doi: 10.1136/jnnp-2013-305383 CrossRefPubMedGoogle Scholar
  10. 10.
    Sousa A (1995) A Variabilidade Fenotípica da Polineuropatia Amiloidótica Familiar: um estudo de Genética Quantitativa em Portugal e na Suécia. ICBAS, Univ Porto, PortoGoogle Scholar
  11. 11.
    Coelho T, Sousa A, Lourenco E, Ramalheira J (1994) A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet 31(4):293–299CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zaros C, Genin E, Hellman U, Saporta MA, Languille L, Wadington-Cruz M, Suhr O, Misrahi M et al (2008) On the origin of the transthyretin Val30Met familial amyloid polyneuropathy. Ann Hum Genet 72(Pt 4):478–484CrossRefPubMedGoogle Scholar
  13. 13.
    Yoshioka K, Furuya H, Sasaki H, Saraiva MJ, Costa PP, Sakaki Y (1989) Haplotype analysis of familial amyloidotic polyneuropathy. Evidence for multiple origins of the Val—Met mutation most common to the disease. Hum Genet 82(1):9–13CrossRefPubMedGoogle Scholar
  14. 14.
    Almeida MR, Aoyama-Oishi N, Sakaki Y, Holmgren G, Drugge U, Ferlini A, Salvi F, Munar-Quès M, et al. (1995) Haplotype analysis of common transthyretin mutations. HumGenetGoogle Scholar
  15. 15.
    Soares ML, Coelho T, Sousa A, Holmgren G, Saraiva MJ, Kastner DL, Buxbaum JN (2004) Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. Eur J Hum Genet 12(3):225–237. doi: 10.1038/sj.ejhg.5201095 CrossRefPubMedGoogle Scholar
  16. 16.
    Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265. doi: 10.1093/bioinformatics/bth457 CrossRefPubMedGoogle Scholar
  18. 18.
    Ii S, Sommer SS (1993) The high frequency of TTR M30 in familial amyloidotic polyneuropathy is not due to a founder effect. Hum Mol Genet 2(8):1303–1305CrossRefPubMedGoogle Scholar
  19. 19.
    Morcillo-Suarez C, Alegre J, Sangros R, Gazave E, de Cid R, Milne R, Amigo J, Ferrer-Admetlla A et al (2008) SNP analysis to results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. Bioinformatics 24(14):1643–1644. doi: 10.1093/bioinformatics/btn241 CrossRefPubMedGoogle Scholar
  20. 20.
    Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42(1):121–130CrossRefPubMedGoogle Scholar
  21. 21.
    Macintyre G, Bailey J, Haviv I, Kowalczyk A (2010) is-rSNP: a novel technique for in silico regulatory SNP detection. Bioinformatics 26(18):i524–i530. doi: 10.1093/bioinformatics/btq378 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M (2014) In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis. Amyloid 21(3):154–162. doi: 10.3109/13506129.2014.900487 CrossRefPubMedGoogle Scholar
  23. 23.
    Chattopadhyay B, Baksi K, Mukhopadhyay S, Bhattacharyya NP (2005) Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci Lett 374(2):81–86CrossRefPubMedGoogle Scholar
  24. 24.
    Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M et al (2012) Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 90(3):434–444CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Sikora JL, Logue MW, Chan GG, Spencer BH, Prokaeva TB, Baldwin CT, Seldin DC, Connors LH (2015) Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). Hum Genet 134(1):111–121. doi: 10.1007/s00439-014-1499-0 CrossRefPubMedGoogle Scholar
  26. 26.
    Norgren N, Hellman U, Ericzon BG, Olsson M, Suhr OB (2012) Allele specific expression of the transthyretin gene in Swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles. PLoS One 7(11):e49981. doi: 10.1371/journal.pone.0049981 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.UnIGENe, IBMC—Institute for Molecular and Cell Biology; Institute for Research and Innovation in Health Sciences (i3S)University of PortoPortoPortugal
  2. 2.ICBAS—Instituto Ciências Biomédicas Abel SalazarUniversidade do PortoPortoPortugal
  3. 3.Unidade Corino de Andrade (UCA), Centro Hospitalar do Porto (CHP)PortoPortugal
  4. 4.UnIGENe, IBMC-i3SPortoPortugal

Personalised recommendations